-
公开(公告)号：JP2010222352A
公开(公告)日：2010-10-07
申请号：JP2010054732
申请日：2010-03-11
发明人： DEGRAW JULI , MORIARTY ANN , LETURCQ DIDIER J , JACKSON MICHAEL R , PETERSON PER A , HEISKALA MARJA
IPC分类号： A61K35/26 , A61K35/12 , A61K35/64 , A61K38/21 , A61K39/00 , A61K41/00 , A61P35/00 , A61P35/04 , A61P37/04 , A61P43/00 , C07K7/06 , C07K7/08 , C12N5/02 , C12N5/07 , C12N5/0783 , C12N5/10 , C12P21/08
CPC分类号： C12N5/0636 , A61K39/0011 , A61K41/00 , A61K48/00 , A61K2035/124 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/55538 , C12N5/0601 , C12N2501/23 , C12N2501/515 , C12N2502/99 , C12N2510/00
摘要： PROBLEM TO BE SOLVED: To provide a cell therapy method for treating tumors. SOLUTION: Artificial antigen presenting cells [AAPC; (Drosophila melanogaster)] transfected with human HLA class I and defined accessory molecules are used to stimulate CD8+T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, and allow for efficient addition of a plurality of peptides that brings the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The generated responses are robust, antigen-specific and reproducible when the peptide epitope is a defined immunogen. The artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译： 要解决的问题：提供用于治疗肿瘤的细胞治疗方法。 解决方案：人造抗原呈递细胞[AAPC; （Drosophila melanogaster）]用人类HLA I类和定义的辅助分子转染，用于刺激来自正常供体和癌症患者的CD8 + T细胞。 在果蝇细胞表面上以高密度表达的I类分子是空的，并且允许有效添加多个肽，其产生识别内源表达特定肽的肿瘤细胞的多克隆应答。 当肽表位是限定的免疫原时，所产生的反应是鲁棒的，抗原特异性的和可重复的。 人造抗原表达系统可适用于治疗绝大多数人群中的大多数癌症。 版权所有（C）2011，JPO＆INPIT
-
公开(公告)号：JP2010235611A
公开(公告)日：2010-10-21
申请号：JP2010108798
申请日：2010-05-10
摘要： PROBLEM TO BE SOLVED: To provide a method of cell therapy for the treatment of tumor, especially the treatment of metastatic melanoma. SOLUTION: This method of cell therapy of a test subject comprises: steps of administration of an effective amount of interferon-α enhancing the expression of a tumor antigen on the surface of tumor to the test subject accompanying melanoma; and inoculation of an effective amount of own cytotoxic T lymphocyte having specificity to the melanoma-related target antigen to the test subject. A method of obtaining the cytotoxic T lymphocyte is also disclosed. COPYRIGHT: (C)2011,JPO&INPIT
摘要翻译： 要解决的问题：提供用于治疗肿瘤的细胞疗法的方法，特别是治疗转移性黑素瘤。 解决方案：该测试对象的细胞治疗方法包括以下步骤：将有效量的干扰素-α施用于肿瘤表面上的肿瘤抗原表达与伴随黑素瘤的测试对象的步骤; 以及将有效量的对黑色素瘤相关的靶抗原具有特异性的本身的细胞毒性T淋巴细胞接种到测试对象。 还公开了获得细胞毒性T淋巴细胞的方法。 版权所有（C）2011，JPO＆INPIT
-
3.发明专利Cytotoxic lymphocyte specific for non-tumor antigen to treat autoimmune and allergic disease 有权非侵袭性淋巴细胞特异性抗肿瘤抗原治疗自身免疫性疾病和过敏性疾病
公开(公告)号：JP2009165482A
公开(公告)日：2009-07-30
申请号：JP2009062554
申请日：2009-03-16
发明人： CAI ZELING , JACKSON MICHAEL R , PETERSON PER A , SHI WEIXING , KONG YAN , DEGRAW JULI
IPC分类号： C12N15/09 , A61K39/00 , A61P3/10 , A61P11/02 , A61P11/06 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/02 , A61P37/08 , C07K14/705 , C12N5/0783
CPC分类号： A61K39/0008 , A61K2035/122 , C12N5/0636 , C12N2501/23 , C12N2501/51 , C12N2501/58 , C12N2502/50 , C12N2502/99
摘要： PROBLEM TO BE SOLVED: To provide a cytotoxic lymphocyte specific for non-tumor antigen to treat autoimmune and allergic diseases. SOLUTION: Provided are an isolated CD8 + T cell having cytotoxicity specific for a target cell, wherein the target cell has one or more non-tumor self-antigen peptides bonded to an MHC class I molecule on the surface of the target cell and the self-antigen peptide is a peptide derived from IgE protein or a peptide derived from CD40L protein; and a non-natural antigen presenting cell derived from Drosophila melanogaster and containing the MHC class I molecule on a cell surface and at least one antigen peptide from human IgE or human CD40L. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译： 要解决的问题：提供对非肿瘤抗原特异性的细胞毒性淋巴细胞，以治疗自身免疫性和过敏性疾病。 解决方案：提供具有靶细胞特异性细胞毒性的分离的CD8
+ T细胞，其中靶细胞具有与MHC I类分子结合的一种或多种非肿瘤自身抗原肽 在靶细胞的表面上，自身抗原肽是衍生自IgE蛋白的肽或衍生自CD40L蛋白的肽; 和源自黑腹果蝇的非天然抗原呈递细胞，并且在细胞表面含有MHC I类分子，以及至少一种来自人IgE或人CD40L的抗原肽。 版权所有（C）2009，JPO＆INPIT -
公开(公告)号：JP2005139118A
公开(公告)日：2005-06-02
申请号：JP2003377653
申请日：2003-11-07
摘要： PROBLEM TO BE SOLVED: To provide a method for isolating, stimulating and expanding a naive cytotoxic T lymphocyte precursor cell (CTLp) to an antigen-specific effector capable of lysing a tumor cell in vivo, to solve the problem wherein T cell response is often diminished in human with a compromised immune system. SOLUTION: The present ex vivo protocol produces a fully functional effector. Artificial antigen presenting cells (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8 + T cells from normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, enabling efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing specific peptides. COPYRIGHT: (C)2005,JPO&NCIPI
摘要翻译： 要解决的问题：为了提供一种将天然细胞毒性T淋巴细胞前体细胞（CTLp）分离，刺激和扩增到能够在体内裂解肿瘤细胞的抗原特异性效应物的方法，以解决其中T细胞 免疫系统受损的人群的反应往往减少。 解决方案：本离体方案产生完全功能的效应物。 用人类HLA I类和定义的辅助分子转染的人造抗原呈递细胞（AAPCs;果蝇）被用于刺激正常供体和癌症患者的CD8 + SP细胞。 在果蝇细胞表面高密度表达的I类分子是空的，能够有效地加载多个肽，从而产生识别内源表达特异性肽的肿瘤细胞的多克隆应答。 版权所有（C）2005，JPO＆NCIPI
-
公开(公告)号：JP2012097117A
公开(公告)日：2012-05-24
申请号：JP2012020842
申请日：2012-02-02
发明人： DEGRAW JULI , MORIARTY ANN , LETURCQ DIDIER J , JACKSON MICHAEL R , PETERSON PER A , HEISKALA MARJA
IPC分类号： A61K35/26 , A61K35/12 , A61K38/21 , A61K39/00 , A61K41/00 , A61P35/00 , A61P35/04 , C07K7/06 , C07K14/47 , C12N1/00 , C12N5/02 , C12N5/07 , C12N5/0783 , C12P21/08
CPC分类号： C12N5/0636 , A61K39/0011 , A61K41/00 , A61K48/00 , A61K2035/124 , A61K2039/5154 , A61K2039/5156 , A61K2039/5158 , A61K2039/55527 , A61K2039/55533 , A61K2039/55538 , C12N5/0601 , C12N2501/23 , C12N2501/515 , C12N2502/99 , C12N2510/00
摘要： PROBLEM TO BE SOLVED: To provide a cell therapy method for the treatment of tumors.SOLUTION: Artificial antigen presenting cells, (AAPCs; Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers in a significant majority of the population.
摘要翻译： 要解决的问题：提供用于治疗肿瘤的细胞治疗方法。 解决方案：用人类HLA I类和定义的辅助分子转染的人造抗原呈递细胞（AAPC;黑腹果蝇）用于刺激来自正常供体和癌症患者的CD8 + T细胞。 在果蝇细胞表面上以高密度表达的I类分子是空的，允许有效负载多个肽，导致产生识别内源表达特定肽的肿瘤细胞的多克隆应答。 如果肽表位是定义的免疫原，所产生的响应是鲁棒的，抗原特异性的和可重复的。 这种人造抗原表达系统可以适应于治疗绝大多数人群中的大多数癌症。 版权所有（C）2012，JPO＆INPIT
-
-
-
-
搜索结果
5 条记录 (耗时 0.035 秒)
